Neurological Effects of IDRA-21


IDRA-21 is yet another obscure compound that is being investigated for its cognitive enhancing properties. This compound has intrigued a good portion of the nootropic community owing to its potency, which initial lab tests have shown to be at least 10 to much as 30 times more powerful than aniracetam. IDRA-21 is an ampakine compound and a derivative of benzothiadiazine.

Ampakines have naturally potent nootropic abilities. These compounds interact with the AMPA receptors in the brain, a process which is thought to result in the enhancement of its primary cognitive processes. It is unclear when IDRA-21 was first discovered and synthesized, but the earliest studies and clinical trials on the compound were done back in 1995.

To date, IDRA-21 is yet to be tested on human subjects. In animal trials, this compound was found to have the ability improve memory and learning skills in rats and in rhesus monkeys. The nootropic effects of a single dosing of IDRA-21 on lab animals were observed to last up to three days. This is thought to be a result of its ability to encourage the induction of long-term synaptic activity within the brain.

IDRA-21 Powder Dose

Current studies on IDRA-21 are focused mainly on its potential as a treatment for a variety of neurological conditions such as Alzheimer’s Disease, Parkinson’s Disease, and cognitive decline that comes with ageing.

Based on the tests done on animals, IDRA-21 provides a long-lasting cognitive enhancement such as improved memory and learning skills on a single dose. While this compound has not been clinically tested on humans, there are a few nootropic users who were able to try out IDRA-21. These users report a variety of cognitive enhancement from using the compound. These include a heightened sensory perception, increased motivation, and a sustained mental focus throughout the day. Some of these users also felt that IDRA-21 may have a positive effect on anxiety and depression.

On the other side of the coin, unofficial and unsubstantiated reports from those who have sampled IDRA-21 report of various side effects, some of which are common to ampakines. These side-effects, which include headaches, dizziness, mood swings, anxiety, insomnia, restlessness, nausea, and sweating usually show up when the nootropic effects of the dose begin to wear off, usually at around 24 to 36 hours after dosing.


  1. Clinical trials show that it is an effective nootropic.
  2. Estimated to be at 10 to 30 times more potent than aniracetam.
  3. A single dose can last for days.
  4. It has a good chance of being a mainstream nootropic.


  1. Very little information about the compound is available.
  2. Toxicity levels and long-term effects have not been researched yet.
  3. Extremely limited availability.
  4. It has unpleasant side effects.

IDRA-21 at this stage is still considered to be an experimental compound. Since there is yet to be a formal study on its effects on humans, proper and safe dosing of IDRA-21 has not been established. There are a lot of nootropic agents available that are generally considered and are tested to be safe. It will be best to use other safer cognitive enhancers for the moment and hold off supplementation with IDRA-21 until further tests are done on the compound.



Speak Your Mind